The surge is attributed to its newer Enhanze-tied products, which are beginning to drive incremental growth. Enhanze is a drug delivery platform that allows large volumes of intravenous medications to be delivered via subcutaneous injection by breaking down a key skin barrier. This comes despite a looming patent expiration in 2029.